This document provides information about high altitude areas and their effects on the human body. It discusses the characteristics of high altitude terrain, such as low oxygen levels, extreme temperatures, and difficult terrain. It then describes the various physiological effects of high altitudes, including lack of oxygen, fatigue, and psychological impacts. The document outlines different medical problems that can occur at altitude, such as altitude sickness, pulmonary edema, cerebral edema, and frostbites. It provides details on prevention, treatment, and the process of acclimatization to high altitude conditions.
It discusses various effects of high altitude on human body in detail, acute mountain sickness, chronic mountain sickness, high altitude pulmonary edema, high altitude cerebral edema, acclimatization
It discusses various effects of high altitude on human body in detail, acute mountain sickness, chronic mountain sickness, high altitude pulmonary edema, high altitude cerebral edema, acclimatization
Medical problems in high altitude- Height does mattermanya1759
High altitudes are frequented by ardent mountaineers or tough soldiers. The medical problems faced at these uninhabitable conditions are discussed only when some catastrophe strikes them like Everest avalanche or Siachen avalanche. The presentation classifies high altitude, the medical problems faced there and management of same.
The above presentation discuss about the environmental challenges faced by the athletes during the sports. The certain factors which affects the atheletes performance in the sports. Factors like wind, temperature, humidity , pollution and altitude and individual effect on the atheletes performance in different sports is been discussed. The content discussed comes under the sports nutrition.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Medical problems in high altitude- Height does mattermanya1759
High altitudes are frequented by ardent mountaineers or tough soldiers. The medical problems faced at these uninhabitable conditions are discussed only when some catastrophe strikes them like Everest avalanche or Siachen avalanche. The presentation classifies high altitude, the medical problems faced there and management of same.
The above presentation discuss about the environmental challenges faced by the athletes during the sports. The certain factors which affects the atheletes performance in the sports. Factors like wind, temperature, humidity , pollution and altitude and individual effect on the atheletes performance in different sports is been discussed. The content discussed comes under the sports nutrition.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
5. TERRAIN AND WEATHER
• Altitude
• Vegetation
• Lack of water
• Paucity of roads and tracks
• Time
• Space
• Variation in temperature
• Speed of wind
• Wind chill
• Movement on snow difficult
8. EFFECTS
• Lack of oxygen
• Movement
• Limited lines of communication
• Weather changes shortly
• UV rays
• Mental and physical stress
• Fatigue
• Motivation
9. EFFECTS
• Altitude > 2700 m (9000 ft)
• Main problem: decreased availability of oxygen causing
a disorder of normal breathing
• Other factors: low temperature
low air humidity
high UV radiation
low atmospheric pressure
8 850 m / 29 000 ft
5 500 m / 18 000 ft
2 700 m / 9 000 ft
pA = 1 [atm]
0 m
pA = 0.75
pA = 0.5
pA = 0.3
O2 - 21 %
13. CHILBLAIN
• Poor blood circulation
• Family history of chilblains
• Regular exposure to cold, damp or draughty conditions
• Poor diet or low body weight.
• Long-term condition that causes swelling in the body's tissues– a
common condition that affects the blood supply to certain parts of the
body, usually the fingers and toes.
• People who smoke are more at risk as nicotine constricts blood vessels.
• Areas of the feet exposed to pressure, such as a toe that's squeezed by
tight shoes.
• Abrupt temp changes.
• People with diabetes are at higher risk.
15. FROSTBITE
• Exposure to severe cold or cold objects.
• Affects fingers, toes, cheeks, nose and ears.
• Tissues freezes at sub zero temperatures.
• May cause gangrene.
• Susceptible to future frostbite.
• Amputation or loss of function.
16. MEDICAL PROBLEMS
• Related to blood clotting disorder
– DVT
– Pulmonary thromboembolism
– CVA
• Eye & skin problems
• Others
– GI disorders
– Neurological & sleep disorders
– Misc & exacerbation of existing disorders
17. OTHER EFFECTS
• Dimness of vision
• Loosening of teeth
• Loss of weight
• Flatulence
• Indigestion
• Loose bowels
• Anemia
20. PRECAUTIONS / MITIGATION
• Knowledge
• Acclimatization
• Special equipment
• Training
• Discipline
• Hygiene and sanitation
• First aid
• Casualty evacuation
• Treatment
21. adequate acclimatization
insufficient high altitude illness
REACTION TO HIGH ALTITUDE
5 000 m
16 500 ft
7 000 m
24 000 ft
2 500 m
8 000 ft
high altitude illness
tolerance zone
current acclimatization
no problems
adaptation
22. PREVENTION OF HAI
1. Gradual ascent within the tolerance zone
2. Full acclimatization
3. Descent when develop symptoms AMS
4. Avoiding medications that cause depression
of breathing
• alcohol, sleeping pills, sedatives, strong
painkillers
5. Prophylaxis
23. • A gradual process of the body adaptation to high altitude
ACCLIMATIZATION
Changes :
1. Breathing: Hyperventilation (breathing deeper and faster)
Shortness of breath during exertion
Changed breathing pattern (periodic breathing)
and frequent awakening at night
2. Blood circulation: Tachycardia (increased heart rate)
Decreased maximum heart rate
Higher number of red blood cells
3. Body fluid : Increased urination (altitude diuresis)
24. ACCLIMATIZATION
• A reversible, non inheritable change in the
anatomy or physiology of an organism that
enables it to survive in stressful environment
• Altitude tolerance
• Qualitatively similar to adaptation
25. PHYSIOLOGICAL CHANGES
• The main features of acclimatization are
related to changes in :
– Respiratory system
– Cardiovascular system
– Oxygen transport and delivery system
• Others
– Endocrines
– Renal functions
– Coagulation
26. ADAPTATION
• Involves biochemical, physiological and
anatomical changes in the organism which
have a genetic basis and is inheritable
• Native highlanders
27. Physiological Adaptation
• Changes usually >2500m (30% decrease in atm
pressure)
• Physiological changes in early adaptation
– Changes in RBCs
• Increased number
• Increase in size and volume
• Increased Hb concentration in RBC
– Increase in pulmonary ventilation and vital capacity
– Increase in Heart rate, Blood volume and Cardiac output
28. Physiological Adaptation
• “Rapid acclimatization” may manifest as early
mountain sickness
• The beneficial adaptive response becomes
aberrant and disease process starts when :
– Acclimatization is inadequate or breaks down
– Ascent is too rapid (more than 3000 ft in a day)
– Heavy physical exertion (un-acclimatized)
– Lag in adjustment of body to increasing hypoxia
– Pronounced symptoms in night due to pooling of blood in
lungs (horizontal position)
29. ACCLIMATIZATION SCHEDULE
• STAGE 1 ( 9000ft – 12000ft ) : 6 DAYS
Day 1& 2 – Rest, short walk , no climb
Day 3& 4 - Slow pace walk for 1.5 km, no
steep climb
Day 5& 6 - 5 km walk with climb of 300m
within the same
30. • STAGE 2 ( 12000ft – 15000ft ) : 4 DAYS
Day 1 & 2 – Slow walk for 1.5 km, no steep
climb
Day 3 - Slow walk upto 3 km & slow
climb of 300m in 3 km without
equipment
Day 4 - Slow walk upto 3 km & slow
climb of 300m in 3 km with
equipment and steep climb of 100m
without equipment
31. • STAGE 3 ( > 15000ft ) – 4 DAYS
Same as in stage 2
RE - ENTRY
Absence from high altitude area for :
• > 4 weeks : full acclimatization
• < 10 days : no acclimatization
• 10 days - 4 weeks : 4 days acclimatization
required at each stage
Day 1 & 2 - rest , short walk
Day 3 - slow walk of 1-2 km , no climb.
Day 4 - slow walk of 3 km , with climb of 300 m
32. PHYSIOLOGICAL ADAPTATION
• Interstitial fluid into vascular compartment >
hypevolemia > overload of pulmonary circulation
• Hyperventilation>>tissue CO2 washout >>hypocapnia
& alkalosis
• Increase in 2,3 DPG brings about major changes -
restores O2 delivery to tissues
33.
34. HIGH ALTITUDE ILLNESS
1. High altitude and Pa O2
2. Acclimatization
3. High altitude illness: AMS
HACO
HAPO
4. Treatment of HAI
5. Prevention of HAI
38. Respiration
• Involves
– Ventilation
– Diffusion
– Gas transport
– Tissue diffusion
• Oxygen moves in a diffusion gradient
• HA alters this gradient (becomes less steep)
• Acclimatization tries to correct this alteration
39. Ventilatory changes
• Hyperventilation within few hours in response to
hypobaric hypoxia (peripheral chemoreceptor
mediated)
• Increase in respiratory rate and subsequently in
amplitude
• Increase in tidal volume
• Drop in arterial CO2 tension – resp alkalosis
40. • Inhibition of central medullary chemo
receptors
• Peripheral chemo receptors are strong and
override the central receptors
• Sensitivity of central receptors to carbon
dioxide returns to normal within 8 days of
ascent
41. Hypoxic ventilatory response
• A basic response to hypoxia via chemo-
receptors
• The foundation of successful
acclimatization
• Sub normal HVR leads to alveolar
hypoventilation causing pulmonary
vasoconstriction
42. Pulmonary diffusion
• The alveolar to arterial difference in oxygen tension
is 6 mm Hg at sea
• This alveolar to arterial difference in oxygen tension
is reduced at HA
• This leads to better arterial oxygen tension
• Also there is an increase in ventilation perfusion ratio
and pulmonary arterial pressure
43. Systemic circulation
• Tachycardia due to increased sympathetic
activity
• Drop in cardiac output and the stroke volume
(up to 20-25% drop)
• Decrease in plasma volume due to diuresis
• Total blood volume increase due to increase in
hematocrit after two to three weeks of stay
44. Oxygen transport
• Oxygen transport and release depends on CO, SaO2
and affinity of Hb with oxygen
• To ensure adequate oxygen to tissue –
– Increase in hemoglobin
– Increase in cardiac output
– Decrease affinity of Hb with oxygen
• Initial Rise in Hb is due to hemo-concentration
resulting from diuresis
• Absence of this diuresis leads to fluid retention and has
been implicated in pathogenesis of AMS
45. • Hb rises within few days
• The rise in Hb and hamatocrit is due to increased
erythropoiesis mediated through erythropoietin
• Erythropoietin also rises within few hours of
ascent
• Hb comes back to normal within 20 days of
descent
46. Tissue diffusion
• Increased oxygen availability from the blood to
the tissues
• Increase in capillary density and decrease in
muscle fiber size
• Myoglobin levels in muscles increase
• Myoglobin facilitates diffusion of oxygen to the
cells
47. Syndromes due to hypobaric hypoxia
• Acute mountain sickness syndrome
– Benign acute mountain sickness
– High altitude pulmonary edema
– High altitude cerebral edema
• Sub acute mountain sickness syndrome
– Adult SAMS
– Infantile SAMS
• Chronic mountain sickness
48. • Others
– High altitude pulmonary arterial hypertension
– High altitude retinopathy
• Other medical problems
– High altitude syncope
– Stroke at HA
– High altitude induced hypertension
49. Forms of HAI:
HIGH ALTITUDE ILLNESS (HAI)
I. Acute mountain sickness (AMS)
II. High altitude cerebral edema (HACO)
III. High altitude pulmonary edema (HAPO)
• A disease caused by hypoxia in high altitude that is
beyond the ranges the body can tolerate
50. ACUTE MOUNTAIN SICKNESS
(AMS)
• Symptoms caused by mild brain swelling (fluid
retention) due to hypoxia
• Mild to severe
incidence 25 – 85 %
usually appears 6 – 12 hours after an ascent
51. • Hypoxia - Increased secretion of atrial
natriuretic peptide
- Activation of renin - angiotensin –
Aldosteron system
• Both these lead to Fluid retention
• Arterial hypoxemia causes cerebral vaso-dilatation
responsible for headache
52. Predisposing factors:
1. Rate of ascent
2. Altitude reached (sleeping altitude)
3. Individual susceptibility (genetic)
4. Other: exertion
certain diseases (cardiopulmonary)
no significant association with: age
gender
physical fitness
ACUTE MOUNTAIN SICKNESS
(AMS)
53. DIAGNOSIS:
Headache
+ 1 or more of the following symptoms:
loss of appetite, nausea, vomiting
fatigue, weakness
dizziness, light-headedness
difficulty sleeping
in the setting of a recent gain in altitude above 2500 m
ACUTE MOUNTAIN SICKNESS
(AMS)
54. The Lake Louise consensus
scoring of AMS
• AMS self assessment
• To diagnose patient should have
– History of recent gain of altitude
– Stay at that altitude for several hours
– Headache
55. • Headache 0 None at all
1 Mild headache
2 Moderate headache
3 Severe headache,
incapacitating
56. • Gastrointestinal symptoms
0 Good appetite
1 Poor appetite or nausea
2 Moderate nausea or vomiting
3 Severe, incapacitating nausea and
vomiting
57. • Fatigue and/or Weakness
0 Not tired or weak
1 Mild fatigue/weakness
2 Moderate fatigue/weakness
3 Severe fatigue/weakness
59. • Difficulty in sleeping
0 Slept as well as usual
1 Did not sleep as well as usual
2 Woke many times, poor night's sleep
3 Could not sleep at all
60. • Score of 3 or more is positive for AMS
• Score of more than 5 indicate severe
disease
61. • Severe swelling of the brain with deterioration of
brain functions
• The most severe form of AMS, end-stage of AMS
Incidence 0.1 - 5 %
often manifests at night
can progress rapidly, lethal in few hours to 2 days
HIGH ALTITUDE CEREBRAL EDEMA
(HACO)
62. HIGH ALTITUDE CEREBRAL EDEMA
(HACO)
Predisposing factors:
like in AMS
HACO usually develops from AMS
63. HIGH ALTITUDE CEREBRAL EDEMA
(HACO)
DIAGNOSIS:
at least 2 of the following symptoms:
AMS
ataxia (loss of coordination of movements)
mental status changes (confusion, disorientation)
in the setting of a recent gain in altitude above 2,500 m
64. Clinical features of HACO
• Isolated HACO is uncommon
• Usually seen in combination with HAPO
• The onset is with AMS
• The transition from AMS to HACO may be
very subtle hence a high degree of suspicion is
needed for diagnosis
65. HACO should be suspected
• Truncal ataxia – tested by tandem walking
(heel to toe walking)
• Alteration in the level of consciousness
66. Other features
• Dimness of vision
• Dizziness and drowsiness
• Incontinence of urine
• Mood changes
• Confusion
• stupor and coma
67.
68. HIGH ALTITUDE PULMONARY EDEMA
(HAPO)
• Leak and accumulation of fluid in the lungs leading
to respiratory failure
• May occur without signs of AMS
Incidence 0.1 - 5 %
often manifests at night (typically the second night of ascent)
progresses rapidly, lethal if untreated
may lead to development of HACO
69. HAPO
• Can be preceded by AMS
• Initial patho-physiology remains same
– Increase in blood volume
– Redistribution of blood from periphery to
centre
• Onset of HAPO is also seen immediately on
arrival to HA by air – direct role of hypoxia
on lungs
70. HIGH ALTITUDE PULMONARY EDEMA
(HAPO)
Predisposing factors:
1. Young fit males
2. Rate of entry (Entry by air – rapid)
3. Physical exercise even of moderate intensity (within 72
hrs of entry into HA)
4. Cold (need further study) Genetic factors
5. Re-exposure to HA
71. Pulmonary edema
• Caused by flow of fluid across capillary
membranes into the interstitial space and
hence in the alveoli
• This flow depends on
– Hydrostatic pressure in the capillary
– The integrity of capillary endothelium
– Rate of removal of fluid from interstitial
space
72. • Pulmonary vasoconstriction and pulmonary
arterial hypertension cause rise in
hydrostatic pressure
• Pulmonary hypertension also causes
epithelial dysfunction
• Epithelial dysfunction also caused by
mediators
73. Major changes
• Non uniform hypoxic pulmonary arteriolar vaso-
constriction
• Pulmonary arterial hypertension
• Increased pulmonary blood flow in regions not
affected by vaso-constriction
• Epithelial dysfunction
74. • Hypoxic vasoconstriction, associated with
increased pulmonary blood flow causes
STRESS FAILURE of the pulmonary
capillaries and with disruption of integrity
of the capillary-alveolar membrane it
leads to pulmonary edema
75. HAPO
DIAGNOSIS:
at least 2 of the following symptoms:
Breathlessness at rest
Cough
Weakness, fatigue, drowsiness
Chest tightness, fullness, congestion
at least 2 of the following signs:
gurgling or rattling breaths, coarse crepts
central cyanosis (blue or dark purple lips)
fast breathing
increased heart rate
in the setting of a recent gain in altitude above 2500 m
76. Diagnosis
• Based on clinical features
• Confirmed on X-ray chest
• Soft, fluffy, non homogenous shadows
77.
78.
79. Severity of HAPO
Mild Moderate Severe
Pulse <120 120 -140 >140
Cyanosis Nil +/- +/-
Resp rate <40 40 – 50 > 50
Conscious Yes Yes Yes/no
Crepitations <1/2 lung
fields
> ½ lung
fields
> ½ lung
fields
80. TREATMENT OF AMS
Mild to moderate forms
NEVER continue ascent !
Consider - rest at the same altitude
- descent
Proper Fluid intake
Mild analgesics (paracetamol, aspirin, ibuprofen)
Acetazolamide (Diamox)- increases ventilation & arterial
O2
Rest
Severe forms: treat like HACO
81. AMS – Specific Treatment
• Acetazolamide
– Prophylactic and curative
– Carbonic anhydrase inhibitor
– Causes bicarbonate diuresis and metabolic acidosis
– Increased ventilation and arterial oxygenation
– Dose 250 mg PO tid
• Dexamethasone
– Reduces cerebral edema
– Useful if acetazolamide not tolerated
– Dose 8mg IM/PO followed by 4mg IM/PO 6 h
• Ginkobiloba
82. TREATMENT OF HACO
Immediate descent to lower altitude
Oxygen inhalation
Hyperbaric bag (HAPO Bag)
Acetazolamide (Diamox)
Dexamethasone
83. TREATMENT OF HAPO
Evacuation to lower altitude
Oxygen inhalation
Hyperbaric bag
Diuretics - Lasix
Nifedipine
84. PORTABLE HYPERBARIC CHAMBER
(HAPO bag)
• Air-impermeable bags that can be inflated to high
pressure, simulating descent
• Main types: Gamow
Certec
PAC (Portable Altitude Chamber)
86. PORTABLE HYPERBARIC CHAMBER
• Indications: HACO or HAPO when descent is impossible
• Contraindications:
Absolute - lack of spontaneous breathing
Relative - middle ear congestion, claustrophobia
87. Recompression
• Recompression in chamber – 1 atm X 16hrs
• All cases of HAPO/ HACO in portable one man
recompression bag
• 150 mm Hg (reduces altitude by 6000 ft); reduce to
50mm Hg every 5 min; recompress 150mm Hg
(ensures air circulation)
• Bring patient out of bag 2 hourly for 15-20 min -
monitoring/ nursing
88.
89.
90. “THE GOLDEN RULES”
If you feel unwell at High Altitude, it is high
altitude illness until proven otherwise
Never ascend with symptoms of AMS
If you are getting worse or have HACO or
HAPO, get down immediately